Allegro Ophthalmics Co-Founder And Cto To Present At The Retinal Innovation Forum At The American Society Of Retina Specialists (Asrs) Annual Meeting

WHO: Vicken Karageozian, M.D., Co-Founder and Chief Technology Officer, Allegro Ophthalmics, will present “Integrin Peptide Therapy: A Novel Approach to Neovascular Eye Diseases” at the Retinal Innovation Forum being held during the 31st Annual Meeting of the American Society of Retina Specialists (ASRS).

WHAT: Dr. Karageozian will present an overview of Allegro and Integrin Peptide Therapy. The presentation will explain the potential benefits to patients and physicians from this novel approach to neovascular eye diseases, and will include the company’s findings to date from human clinical studies in DME and wet AMD.
Dr. Karageozian will also briefly discuss plans for future studies. A discussion and Q&A session will follow. The ASRS Retinal Innovation Forum will be moderated by Mark Humayun, M.D., Ph.D., and Peter Kaiser, M.D.

WHEN: Monday, August 26, 2013 – 3:01-3:11 PM

Sheraton Centre Toronto, Grand Ballroom (lower concourse)
123 Queen St. W, Toronto, Canada

With more than 100 years of combined experience in vision science and medicine, the leadership team at Allegro Ophthalmics, LLC, is establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema, which together affect nearly six million Americans. Allegro Ophthalmics seeks to prevent vision loss and combat blindness, potentially offering millions an improved quality of life sustained by self-sufficient, functional vision.

Michele Gray